CEO COMMENTS

Kristina Torfgård comments Q4 report 2025

“Over the past year, we have made significant progress across our research portfolio while continuously working to streamline operations and conserve resources. We have successfully advanced IRL757 in clinical development, strengthened the patent protection, clarified and confirmed the commercial potential of mesdopetam, reported promising Phase IIb results, and received strong support from leading experts for the continued development of pirepemat. In addition, we have initiated an exciting collaboration with the Danish biotech company Biomia, further expanding the opportunities to leverage our ISP research platform and our expertise in CNS disorders. Our continued focus on prioritization, resource efficiency, and strategic partnerships provides a strong foundation for ongoing innovation and long-term value creation.

Key Milestones During the Quarter and after:

• IRL757 study in PD and apathy approved to start in Europe, funded by MSRD.
• Market research confirms a significant need for new treatments for LIDs- mesdopetam’s differentiated clinical profile is considered attractive.
• Collaboration with Biomia initiated, utilizing the ISP platform to evaluate new CNS compounds
• Strong support from leading international experts for pirepemat and its development strategy.

Together, these advances demonstrate that IRLAB is well on its way to realizing its vision and creating value for patients, partners, and shareholders.”

LATEST INTERIM REPORTS

LATEST ANNUAL REPORT

FINANCIAL CALENDAR

NEXT

February 25, 2026

Year-end report 2025